Frontiers in Medical Sciences Lecture-322

Author: ZSSOM    UpdateTime: 2018/03/09    Hits: 9

Chairs: Speaker1: Prof. Weiping Zou, University of Michigan School of Medicine,Speaker2: Prof.Yangxin Fu, UT Southwestern, Dallas

Time: Mar.16, at 9:00,Mar 16, 2018

Venue: Venue: Lecture Hall, 15th Floor, Science Building, SYSU

About the speaker1

Dr. Zou is the Charles B. de Nancrede professor and a professor of Surgery, Immunology and Biology at the University of Michigan School of Medicine.  He is also the Co-Director of Cancer Hematopoiesis and Immunology Program. Within the University of Michigan Comprehensive Cancer Center, he directs the Immunologic Monitoring Core and the Surgical Oncology Fellow Training (T32) program.Dr. Zou has delivered more than 200 invited lectures at different institutions and conferences, published more than 120 articles and book chapters including 16 in the series of journals of Nature, Science, and Cell, and provided 7 authority reviews and commentary articles in Nature and Science journals. Dr. Zou leads a laboratory staff whose primary focus is tumor immunology and immunotherapy.  His laboratory is one of the most cited research teams in the field of immunology. Its work has been highlighted by many scientific news agencies. The single original work on Tregs has been cited nearly 4,000 times.

About the speaker2

Dr. Fu is a professor of Pathology, and his research area is Immunotherapy and Immunopathology in cancer and infectious diseases. His current research interests include investigating and understanding the mechanisms underlying IR-induced extrinsic resistance as well as testing newly developed personalized immunotherapies to overcome these resistance mechanisms for improved and long-lasting tumor control. After completing his clinical training in pathology at Washington University in St. Louis (1998), Dr. Fu organized his own team to focus his research on understanding the role of the lymphoid microenvironment in cellular and humoral immune responses using various TNF superfamily members such as the LIGHT/lymphotoxin pathway. His team has published more than 50 papers relating to the mechanistic understanding of autoimmunity and immunity against pathogens and tumor in top journals. He has directed clinical, translational, and preclinical studies in immunology––tumor immunology in particular––for more than 15 years. Recently, his team has been developing novel immunotherapeutic molecules, antibodies and armed antibodies by protein engineering.


Upcoming Events

Upcoming Events